U.S., June 17 -- ClinicalTrials.gov registry received information related to the study (NCT07649252) titled 'A Study of Patient Characteristics and Treatment Patterns in Real-world Melanoma Patients Treated With Dabrafenib and Trametinib or Encorafenib and Binimetinib in Japan' on June 11.
Brief Summary: The aim of this study was to describe the patient profile and treatment patterns of adult melanoma patients that were treated with either dabrafenib and trametinib (Dab+Tram) or encorafenib and binimetinib (Enco+Bini) between 01 January 2012 and 30 November 2021 in Japan.
Study Start Date: Aug. 01, 2022
Study Type: OBSERVATIONAL
Condition:
Melanoma
Recruitment Status: COMPLETED
Sponsor: Novartis Pharmaceuticals
Published by HT Digit...